Webinars


Post-Transplant DSA Monitoring

50.1 - Post-Transplant DSA Monitoring: What’s the Point

Presenter: Peter, Nickerson, Winnipeg, MB, Canada
Authors: Peter Nickerson


In the era of modern immunosuppression, rates of acute rejection have significantly decreased thereby improving short-term outcomes but with only modest improvement in long-term graft survival. We, and others, have demonstrated that de novo HLA donor specific antibody (DSA), which correlates with chronic antibody-mediated rejection (cAMR), is the primary cause of late graft loss. The target of the inflammation and injury related to DSA is the microvascular endothelium, and the principle mediators are complement and NK/Macrophage activation. At present, cAMR is diagnosed after the onset of non-specific graft dysfunction (rising creatinine or new onset proteinuria) in which a biopsy confirms microvascular inflammation in association with a DSA documented in the sera. We reported that de novo DSA is detectable in the serum prior to the onset of cAMR-mediated dysfunction (mean 20 months). Therefore the utility of post-transplant DSA monitoring will be reviewed.


You must be logged in to view recordings

Important Disclaimer

By viewing the material on this site you understand and accept that:

  1. The opinions and statements expressed on this site reflect the views of the author or authors and do not necessarily reflect those of The Transplantation Society and/or its Sections.
  2. The hosting of material on The Transplantation Society site does not signify endorsement of this material by The Transplantation Society and/or its Sections.
  3. The material is solely for educational purposes for qualified health care professionals.
  4. The Transplantation Society and/or its Sections are not liable for any decision made or action taken based on the information contained in the material on this site.
  5. The information cannot be used as a substitute for professional care.
  6. The information does not represent a standard of care.
  7. No physician-patient relationship is being established.

Our Corporate Sponsors

TTS gratefully acknowledges the Corporate Partners whose generous support makes the work of the Society possible:

  • astellas
  • roche
  • sanofi